Charles Coombes, MD, PhD, on Clinical Implications of Using Samuraciclib With Fulvestrant for HR–Positive HER2–Negative Breast Cancer

Posted: Tuesday, March 8, 2022

Charles Coombes, MD, PhD, of Imperial College, London, discusses what the results of his research on a first-in-class, oral, selective inhibitor of CDK7 used in combination with fulvestrant could mean for patients with advanced hormone receptor–positive, HER2– negative breast cancer who have progressed on their prior CDK4/6 inhibitor treatment.